Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17,566 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time.
Chia S, Low JL, Zhang X, Kwang XL, Chong FT, Sharma A, Bertrand D, Toh SY, Leong HS, Thangavelu MT, Hwang JSG, Lim KH, Skanthakumar T, Tan HK, Su Y, Hui Choo S, Hentze H, Tan IBH, Lezhava A, Tan P, Tan DSW, Periyasamy G, Koh JLY, Gopalakrishna Iyer N, DasGupta R. Chia S, et al. Among authors: su y. Nat Commun. 2017 Sep 5;8(1):435. doi: 10.1038/s41467-017-00451-5. Nat Commun. 2017. PMID: 28874669 Free PMC article.
Clinical efficacy and long-term immunogenicity of an early triple dose regimen of SARS-CoV-2 mRNA vaccination in cancer patients.
Lee MX, Peng S, Lee ARYB, Wong SY, Tay RYK, Li J, Tariq A, Goh CXY, Tan YK, Tan BKJ, Teo CB, Chan E, Ooi M, Chng WJ, Chee CE, Ho CLF, Walsh RJ, Wong M, Su Y, Alexander L, Sethi SK, Tan SSY, Chan YH, Tan KB, Lee SC, Chai LYA, Sundar R. Lee MX, et al. Among authors: su y. Ann Acad Med Singap. 2023 Jan;52(1):8-16. doi: 10.47102/annals-acadmedsg.2022302. Ann Acad Med Singap. 2023. PMID: 36730801 Free article.
Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study.
Jin ZC, Chen JJ, Zhu XL, Duan XH, Xin YJ, Zhong BY, Chen JZ, Tie J, Zhu KS, Zhang L, Huang M, Piao MJ, Li X, Shi HB, Liu RB, Xu AB, Ji F, Wu JB, Shao GL, Li HL, Huang MS, Peng ZY, Ji JS, Yuan CW, Liu XF, Hu ZC, Yang WZ, Yin GW, Huang JH, Ge NJ, Qi X, Zhao Y, Zhou JW, Xu GH, Tu Q, Lin HL, Zhang YJ, Jiang H, Shao HB, Su YJ, Chen TS, Shi BQ, Zhou X, Zhao HT, Zhu HD, Ren ZG, Teng GJ; CHANCE2201 Investigators. Jin ZC, et al. Among authors: su yj. EClinicalMedicine. 2024 May 6;72:102622. doi: 10.1016/j.eclinm.2024.102622. eCollection 2024 Jun. EClinicalMedicine. 2024. PMID: 38745965 Free PMC article.
17,566 results
You have reached the last available page of results. Please see the User Guide for more information.